Literature DB >> 3909133

Oral meptazinol--United Kingdom experience.

J A Henry.   

Abstract

An oral formulation of meptazinol has been developed and marketed in the United Kingdom. The 200 mg tablet has a potency similar to dextropropoxyphene 32.5 mg/paracetamol 325 mg or pentazocine 50 mg. Nausea is the major side effect and constipation and dysphoria are virtually absent. Though a variable first pass metabolism restricts its potential for use in severe pain, oral meptazinol provides effective analgesia in mild or moderate pain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3909133

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  2 in total

Review 1.  Opioid agonist-antagonist drugs in acute and chronic pain states.

Authors:  P J Hoskin; G W Hanks
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Quantitative autoradiographic distribution of meptazinol-sensitive binding sites in rat brain.

Authors:  B A Adler; R R Goodman; G W Pasternak
Journal:  Cell Mol Neurobiol       Date:  1988-12       Impact factor: 5.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.